BridgeBio Secures Growth Capital
BridgeBio Secures $1 Billion Preferred Equity to Drive New Genetic Drug Launches
Key Points
The financing instrument is Series A Cumulative Convertible Participating Preferred Stock with a 7.00% dividend, payable in kind or cash at BridgeBio's election, and an initial conversion price of $137.79 per share that increases to $153.10 per share after five years; the security is permanent equity with no scheduled maturity and includes BridgeBio's right to redeem for cash or convert under the definitive agreements.
Sixth Street is contributing roughly $800 million of the up-to-$1 billion financing, with HealthCare Royalty (a business of KKR) participating to reach the total potential proceeds of up to $1 billion, according to press coverage of the deal.
The initial conversion price is stated as a premium to BridgeBio's 30-day VWAP (approximately $137.79 per share) with a schedule that increases to $153.10 per share in five years, reflecting a strong upside for investors while underpinning BridgeBio's equity-heavy capital structure.
Analyst coverage adjusted in response to BridgeBio's financing and near-term launches: Mizuho lowered its price target to $96 from $106 while maintaining an Outperform rating, and Canaccord Genuity initiated coverage with a Buy rating and a $104 price target, highlighting Attruby and other near-term launch potential and infigratinib's profile.
BridgeBio Pharma has raised $1 billion in convertible preferred equity from Sixth Street and HealthCare Royalty, a business of KKR, to fund the simultaneous launch of multiple genetic-disease drugs. The deal gives the California biotech a major cash runway without forcing it to sell new common shares and dilute existing investors, according to Investing.com.
Sixth Street is contributing roughly $800 million of the total, with HealthCare Royalty adding about $200 million. CEO Neil Kumar said the financing "strengthens our balance sheet for the long term" and gives BridgeBio "flexibility to maximize the value" of its pipeline, according to GJ Sentinel.
How the Preferred Stock Deal Actually Works
The security is called Series A Cumulative Convertible Participating Preferred Stock. It pays a 7.00% annual dividend that BridgeBio can pay in cash or in extra shares of preferred stock. That option to skip cash payments is a key benefit — it lets the company keep more money on hand during the expensive launch period, according to Post Register.
Investors can eventually convert their preferred shares into common stock at $137.79 per share — a significant premium to BridgeBio's recent trading price. That price steps up to $153.10 per share after five years. Crucially, there is no scheduled maturity date and holders cannot force BridgeBio to buy the shares back, making this permanent equity rather than debt.
Three New Drug Launches Driving the Capital Need
BridgeBio is preparing three near-term U.S. launches. BBP-418 targets LGMD2I, a form of Limb-Girdle Muscular Dystrophy with no approved therapy. Encaleret is aimed at ADH1, a rare calcium disorder that also lacks any targeted treatment. Infigratinib targets achondroplasia, the most common form of short-limb dwarfism, according to Goldea Capital.
All three launches require large sales forces and marketing spend before drug revenue fully arrives — a costly gap common in biotech. The $1 billion provides a buffer. Meanwhile, Attruby, BridgeBio's heart drug already on the market, is projected to reach peak annual sales of $2.5 billion to $4 billion, according to J.P. Morgan estimates cited in research briefings.
Infigratinib Targets BioMarin's Achondroplasia Market
In the achondroplasia space, BridgeBio's infigratinib could shake up the market. BioMarin's Voxzogo currently dominates with a daily injection. Infigratinib is an oral drug, which analysts say could pull patients away from injections, making the $1 billion "war chest" critical for the competitive rollout. Canaccord Genuity analyst Whitney Ijem called infigratinib's potential "underappreciated," initiating coverage with a Buy rating and a $104 price target, according to Investing.com.
Analysts See Upside Despite a Trimmed Price Target
Mizuho analyst Salim Syed kept an Outperform rating on BridgeBio but cut his price target from $106 to $96. He cited the added complexity of the preferred equity structure and its 7% dividend obligation as reasons for the trim. Still, both Mizuho and Canaccord remain bullish on the company's overall pipeline prospects, according to Investing.com.
Sixth Street's Vijay Mohan said the deal reflects "confidence in BridgeBio's ability to bring meaningful medicines to patients." For common shareholders, the big question is whether BridgeBio's stock can climb past $137.79 — the initial conversion price — before the preferred shares convert and add to the share count. If the drugs succeed, analysts say the math works out strongly in everyone's favor, according to GJ Sentinel.
Sentiment
Mostly PositivePublishers
13
Articles
44
Reach
57
